CPIX — Cumberland Pharmaceuticals Share Price
Last trade - 00:00- $127.21m
- $123.01m
- $44.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.29 | ||
| Price to Tang. Book | 7.31 | ||
| Price to Free Cashflow | 203.86 | ||
| Price to Sales | 4.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.77% | ||
| Return on Equity | -42.92% | ||
| Operating Margin | -30.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 35.99 | 42.01 | 39.55 | 37.87 | 44.52 | n/a | n/a | 3.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever.
Directors
- A. Kazimi CHM (62)
- John Hamm CFO (65)
- Martin Cearnal EVP (76)
- Leo Pavliv EVP (60)
- James Herman SVP (65)
- Gordon Bernard IND (69)
- Joseph Galante IND (71)
- Jonathan Griggs IND (86)
- Joey Jacobs IND (67)
- James Jones IND (73)
- Kenneth Krogulski IND (64)
- Caroline Young IND (46)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 7th, 1999
- Public Since
- August 11th, 2009
- No. of Shareholders
- 87
- No. of Employees
- 93
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 14,983,107
- Address
- 1600 West End Avenue, Suite 1300, NASHVILLE, 37203
- Web
- https://www.cumberlandpharma.com/
- Phone
- +1 6152550068
- Auditors
- Carr, Riggs & Ingram, LLC
Latest News for CPIX
Upcoming Events for CPIX
Cumberland Pharmaceuticals Inc. To Update On It’s DMD Program
Q3 2026 Cumberland Pharmaceuticals Inc Earnings Release
Q4 2026 Cumberland Pharmaceuticals Inc Earnings Release
Similar to CPIX
Alkermes
NASDAQ Global Select Market
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 20:09 UTC, shares in Cumberland Pharmaceuticals are trading at $8.49. This share price information is delayed by 15 minutes.
Shares in Cumberland Pharmaceuticals last closed at $8.49 and the price had moved by +211.92% over the past 365 days. In terms of relative price strength the Cumberland Pharmaceuticals share price has outperformed the S&P500 Index by +177.88% over the past year.
The overall consensus recommendation for Cumberland Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCumberland Pharmaceuticals does not currently pay a dividend.
Cumberland Pharmaceuticals does not currently pay a dividend.
Cumberland Pharmaceuticals does not currently pay a dividend.
To buy shares in Cumberland Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.49, shares in Cumberland Pharmaceuticals had a market capitalisation of $127.21m.
Here are the trading details for Cumberland Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CPIX
Based on an overall assessment of its quality, value and momentum Cumberland Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cumberland Pharmaceuticals is $8.50. That is 0.12% above the last closing price of $8.49.
Analysts covering Cumberland Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cumberland Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +153.76%.
As of the last closing price of $8.49, shares in Cumberland Pharmaceuticals were trading +77.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cumberland Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cumberland Pharmaceuticals' management team is headed by:
- A. Kazimi - CHM
- John Hamm - CFO
- Martin Cearnal - EVP
- Leo Pavliv - EVP
- James Herman - SVP
- Gordon Bernard - IND
- Joseph Galante - IND
- Jonathan Griggs - IND
- Joey Jacobs - IND
- James Jones - IND
- Kenneth Krogulski - IND
- Caroline Young - IND